CAMBRIDGE, Mass., January 3, 2024 – Cerberus Therapeutics, Inc., an early-stage biotechnology company focused on development of proprietary nanobody-based platforms to create novel immunotherapeutics, today announced the appointment of Jim Weissman, former Chief Operating Officer and Chief Business Officer of Dicerna Pharmaceuticals Inc., to its Board of Directors.
“Jim is a veteran pharmaceutical executive with decades of experiences in business development and deal makings,” said Novalia Pishesha, Ph.D., Chief Executive Officer and Co-Founder of Cerberus Therapeutics. “I look forward to working with Jim and leveraging his unique expertise to help Cerberus navigate through our business development and partnering strategy.”
Mr. Weissman was most recently the COO and CBO of Dicerna Pharmaceuticals, acquired by Novo Nordisk in December 2021. Prior to Dicerna, he was Vice President of Mankind Corporation. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In this position, Mr. Weissman was responsible for the sales, profit and strategic targets for the company’s specialty products, including CNS, endocrinology, ophthalmology, oncology and diversified portfolios. Mr. Weissman holds a Bachelor of Science from Bates College in Maine.
About Cerberus Therapeutics
Founded in 2021 by Novalia Pishesha, Ph.D., Prof. Hidde Ploegh, Ph.D. and Prof. Harvey Lodish, Ph.D., Cerberus Therapeutics’ nanobody-based technology comprises two distinct platforms: one that targets autoimmunity and one aimed at infectious disease. Leveraging the unique biochemical properties and excellent targeting capabilities of alpaca-derived nanobodies (variable domains of heavy chain-only antibodies), Cerberus’ technology has the potential to reset the immune system and have it rewire itself for therapeutic gain.
Cerberus Contact:
Xiaohong Sang
617-416-6228
xsang@cerberustx.com